Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb
In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and PSMA, or CD28 and EGFR, synergized with an anti-PD-1 mAb to activate T cells and block tumor growth in mouse models of prostate and skin cancer; the combination also induced antitumor immunity.

In January, the company showed that CD28 bispecifics enhanced the efficacy of anti-CD3 bispecifics in mouse models of prostate and ovarian cancer (see “Regeneron’s costimulatory bispecifics paired with anti-CD3 bispecifics”)...